Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Central Neuropathic Pain Due to Multiple Sclerosis
2008-002560-34Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuralgia comparing Duloxetine 60 mg once daily with Placebo (2 arms). Primary endpoint: Primary efficacy: weekly mean of 24-hour average pain severity at 6 weeks. Started Jul 2008; status: completed.
02
Drugs
duloxetine
03
Conditions
Neuralgia
Beyond the preview
Go deeper on 2008-002560-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002560-34.